Overview

The Supreme Court of Canada (SCC) released its much-anticipated decision in Pharmascience Inc. v. Janssen Inc., 2026 SCC 26, addressing the patentability of methods of medical treatment (MMT). In particular, the court was asked to determine whether claims to a dosage regimen in a Janssen patent were patentable subject matter. In a 158-page decision, the SCC affirmed the Federal Court of Appeal’s (FCA) decision that the dosage regimen claims were not MMT and therefore patentable subject matter. Lengthy concurring minority reasons supported the outcome but found that MMT are not inherently unpatentable.

Background

Janssen markets INVEGA SUSTENNA® (paliperidone palmitate) for the treatment of schizophrenia and related disorders. Janssen’s Canadian Patent No. 2,655,335 (335 Patent) teaches a dosing regimen. Patients are to receive a first and second loading dose followed by maintenance doses at specific concentrations on specific days.

Pharmascience Inc. (PMS) sought a notice of compliance to market a generic version of INVEGA SUSTENNA®. Janssen commenced an infringement action under section 6 of the Patented Medicines (Notice of Compliance) Regulations. PMS defended the action on a number of grounds, including that claims of the 335 Patent are invalid for claiming an unpatentable MMT. The Federal Court (FC) found the claims of the 335 Patent valid. PMS appealed to the SCC solely on whether the 335 Patent was an invalid MMT.

PMS asked the SCC to broaden the test for an unpatentable MMT such that the number and scope of medical patents in Canada would be dramatically reduced. Janssen invited the court to uphold the 335 Patent by ruling that an MMT is patentable subject to the existing criteria of the Patent Act (i.e., new, useful, non-obvious). Janssen and several innovative industry interveners asserted that the SCC’s 50-year-old seminal case (Tennessee Eastman) prohibiting MMT should be revisited. Tennessee Eastman relied upon s 41(1) of the Patent Act, which prohibited claims to the medicine but has since been repealed.

SCC majority’s approach for assessing whether a patent claims a prohibited MMT

The majority (Jamal J) of the SCC opted to maintain the status quo by effectively endorsing the FCA’s approach for assessing MMT claims. The SCC also agreed with the FCA and lower court that whether a claimed dosage regimen is fixed or variable is not determinative of the issue.

A patent impermissibly claims an MMT only if it seeks to monopolize professional medical skill and judgment. To determine whether the subject matter amounts to professional medical skill and judgment:

  • Construe the claims, purposively, to determine the subject matter. Substance should be privileged over form.
  • Three guiding factors, which are not exhaustive and do not establish bright-line rules, that may be considered include.
  1. Determining whether the subject matter is or continues to be an appropriate treatment for a particular patient will generally not affect its patentability.
  2. The more the subject matter involves tailoring treatment to the circumstances of individual patients, the more likely it amounts to an invalid MMT.
  3. The more a medical professional would be able to develop or improve the subject matter in the ordinary course of treating patients, the more likely it amounts to an invalid MMT.
  • In the final analysis, the determination must be guided by the facts of each case and the jurisprudence of the federal courts.

Concurring minority held that methods of medical treatment are not inherently unpatentable

A lengthy concurring minority decision (O’Bonsawin and Moreau JJ) upheld the result but concluded there should no longer be a blanket prohibition against patenting MMT. The minority held that the precedential value of Tennessee Eastman is doubtful since the repeal of s. 41. The MMT doctrine has not otherwise been squarely before the SCC until now.

Patenting an MMT should be assessed in the same manner as any other claimed invention using the well-established requirements of patentability and without resort to any de facto skill and judgment test. This approach would not mean all MMT are patentable.

Link to decision.

Norton Rose Fulbright Canada LLP (Orestes Pasparakis and Kristin Wall) acted for the intervener, Innovative Medicines Canada and BIOTECanada.

Contact